Department of Medical Oncology, Oncology Institute, Istanbul University, Istanbul, Turkey.
Oral Oncol. 2011 Jul;47(7):660-4. doi: 10.1016/j.oraloncology.2011.04.010. Epub 2011 May 18.
Radiotherapy (RT) with concomitant chemotherapy (CT) has improved the therapeutic outcome of patients with locally advanced nasopharyngeal carcinoma (LANC). However, the importance of induction CT before definitive therapy is still undefined. Patients (n=59) who had LANC were included in this retrospective study. They received induction CT consisting of cisplatin and docetaxel followed by definitive RT with cisplatin. The median age was 49 years (18-68). All patients were of stages II (15%), III (63%) and IV (22%). Fifty eight patients could receive 3 cycles of CT. Except one patient, there was no grade 3 or 4 toxicity during induction CT. Chemoradiotherapy could be given to 49 patients (83%). Twelve percent of patients had complete response after induction CT and this number had increased to 95% after the completion of the therapy. Objective responses (complete and partial) were 100% after the completion of the therapy. Median follow up time was 29 months. Nine patients had relapse (2 had local only, 4 distant, 3 local and distant). Three patients who had both local and distant relapse died during follow-up. Three year overall and progression free survival rates were 94.9% and 84.7%, respectively. Induction CT with docetaxel and cisplatin is a feasible and tolerable treatment for patients with LANC.
放疗（RT）联合化疗（CT）改善了局部晚期鼻咽癌（LANC）患者的治疗效果。然而，在明确治疗前进行诱导 CT 的重要性仍未确定。本回顾性研究纳入了 59 名患有 LANC 的患者。他们接受了顺铂和多西他赛诱导 CT，随后接受顺铂明确放疗。中位年龄为 49 岁（18-68 岁）。所有患者均为 II 期（15%）、III 期（63%）和 IV 期（22%）。58 例患者可接受 3 个周期 CT。除 1 例患者外，诱导 CT 期间无 3 级或 4 级毒性。49 例（83%）患者可接受化放疗。12%的患者在诱导 CT 后有完全缓解，这一数字在治疗完成后增加到 95%。在治疗完成后，客观缓解（完全缓解和部分缓解）率为 100%。中位随访时间为 29 个月。9 例患者复发（2 例局部，4 例远处，3 例局部和远处）。3 例局部和远处复发的患者在随访期间死亡。3 年总生存率和无进展生存率分别为 94.9%和 84.7%。多西他赛和顺铂诱导 CT 是 LANC 患者可行且耐受的治疗方法。
